Optimized scoring of end-to-end dosimetry audits for passive motion management - A simulation study using the IROC thorax phantom

Dosimetry audits for passive motion management require dynamically-acquired measurements in a moving phantom to be compared to statically calculated planned doses. This study aimed to characterise the relationship between planning and delivery errors, and the measured dose in the Imaging and Radiation Oncology Core (IROC) thorax phantom, to assess different audit scoring approaches. Treatment plans were created using a 4DCT scan of the IROC phantom, equipped with film and thermoluminescent dosimeters (TLDs). Plans were created on the average intensity projection from all bins. Three levels of aperture complexity were explored: dynamic conformal arcs (DCAT), low-, and high-complexity volumetric modulated arcs (VMATLo, VMATHi). Simulated-measured doses were generated by modelling motion using isocenter shifts. Various errors were introduced including incorrect setup position and target delineation. Simulated-measured film doses were scored using gamma analysis and compared within specific regions of interest (ROIs) as well as the entire film plane. Positional offsets were estimated based on isodoses on the film planes, and point doses within TLD contours were compared. Motion-induced differences between planned and simulated-measured doses were evident even without introduced errors Gamma passing rates within target-centred ROIs correlated well with error-induced dose differences, while whole film passing rates did not. Isodose-based setup position measurements demonstrated high sensitivity to errors. Simulated point doses at TLD locations yielded erratic responses to introduced errors. ROI gamma analysis demonstrated enhanced sensitivity to simulated errors compared to whole film analysis. Gamma results may be further contextualized by other metrics such as setup position or maximum gamma.

Monte Carlo modelling and validation of the elekta synergy medical linear accelerator equipped with radiosurgical cones

Monte Carlo simulations of medical linear accelerator heads help in visualizing the energy spectrum and angular spread of photons and electrons, energy deposition, and scattering from each of the head components. Hence, the purpose of this study was to validate the Monte Carlo model of the Elekta synergy medical linear accelerator equipped with stereotactic radio surgical connical collimators. For this, the Elekta synergy medical linear accelerator was modelled using the EGSnrc Monte Carlo code. The model results were validated using the measured data. The primary electron beam parameters, beam size, and energy were tuned to match the measured data; a dose profile with a field size of 40 × 40 cm² and percentage depth dose with a field size of 10 × 10 cm² were matched during tuning. The validation of the modelled data with the measurement results was performed using gamma analysis, point dose, and field size comparisons. For small radiation fields, relative output factors were also compared. The gamma analysis revealed good agreement between the Monte Carlo modeling results and the measured data. A gamma pass rate of more than 95% was obtained for field sizes of 40 × 40 cm² to 2 × 2 cm² with gamma criteria of 1% and 1 mm for the dose difference (DD) and distance to agreement (DTA), respectively; this gamma pass rate was more than 98% for the corresponding values of 2% and 2 mm for the DD and DTA, respectively. A gamma pass rate of more than 99% was obtained for a percentage depth dose with 1 mm and 1% criteria. The field size was also in good agreement with the measurement results, and the maximum deviation observed was 1.1%. The stereotactic cone field also passed this analysis with a gamma pass rate of more than 98% for dose profiles and 99% for the percentage depth dose. The small field output factor exhibited a deviation of 4.3%, 3.4%, and 1.9% for field sizes of 5 mm, 7.5 mm, and 10 mm, respectively. Thus, the Monte Carlo model of the Elekta Linear accelerator was successfully validated. The validation of radio surgical cones passed the analysis in terms of the dose profiles and percentage depth dose. The small field relative output factors exhibited deviations of up to 4.3%, and to resolve this, detector-specific and field-specific correction factors must be derived.

Evaluating the effect of high-density measurement mode on patient-specific quality assurance for head and neck cancer with ArcCHECK

The high-density measurement (HDm) mode of the ArcCHECK device can achieve a twofold resolution enhancement compared to the standard measurement (Sm) mode. The aim of this study was to evaluate the effect of HDm on the gamma passing rate (GPR) for the patient-specific quality assurance (PSQA) in head and neck cancer. We retrospectively evaluated 30 patients who underwent volumetric modulated arc therapy (VMAT) for head and neck cancer. Absolute gamma analysis was performed on Sm and HDm data. We also investigated correlations between the modulation complexity score for VMAT (MCSv) and differences in the GPR between the two measurement modes. The global GPR of Sm and HDm was 81.0% ± 8.4% and 82.6% ± 7.6% for the 2%/2 mm criterion, 94.0% ± 4.1% and 94.9% ± 3.6% for the 3%/2 mm criterion, and 96.6% ± 2.4% and 97.0% ± 2.4% for the 3%/3 mm criterion, respectively. HDm slightly improved GPR (p < 0.01) for the 2%/2 mm criterion. Differences in GPR between Sm and HDm for the 2%/2 mm, 3%/2 mm, and 3%/3 mm criteria were 1.6% ± 3.0%, 0.8% ± 2.0%, and 0.4% ± 1.2%, respectively. No correlation was identified between the MCSv and the difference in GPR between Sm and HDm. Despite an improvement in GPR with HDm, the difference in GPR between Sm and HDm was approximately 2% even when the tighter criteria were used. Moreover, the change in the GPR between Sm and HDm did not depend on plan complexity. Thus, the effect of HDm on GPR is limited for the PSQA in VMAT for head and neck cancer.

Varian eclipse stereotactic 5 mm cone data commissioning

Conical collimators are effective and readily available accessories for the field shaping of small stereotactic fields, however the measurements required to accurately characterise the smallest radiation fields are difficult, prone to large errors, and there is little published commissioning data to compare measurements against. The aim of this investigation was to commission the cone dose calculation algorithm of a Varian Eclipse treatment planning system for a Varian 5 mm cone attached to a Varian TrueBeam linear accelerator beam-matched to the Varian Golden Beam Data (GBD). Tissue maximum ratios (TMRs) and off-axis ratios (OARs) were measured using PTW 60019 microDiamond and PTW 60018 SRS Diode detectors for a flattening filter free 6MV beam. The output factor (OF) was measured with the microDiamond and EBT-XD film. Results were compared to the GBD for this cone and an OF measured by the Australian Clinical Dosimetry Service during an independent audit. Film dosimetry was used to evaluate Eclipse dose calculations in a solid water phantom and end-to-end accuracy with an anthropomorphic head phantom. Output correction factors were derived from IAEA TRS-483. Gamma analysis was used to compare measured TMRs and OARs, and to compare Eclipse dose planes with film dosimetry results. Comparisons between measured and GBD TMRs passed gamma analysis within the specified criteria, while differences between distances to agreement for OARs measured with different detectors was attributed to different volume averaging characteristics. The OFs measured with the microDiamond and film agreed within measurement uncertainty. It was decided to configure Eclipse with the microDiamond measured OF and the SRS Diode measured TMR and OAR data. This was validated with various comparisons carried out to confirm both measurement accuracy and Eclipse configuration.

Isodoses-a set theory-based patient-specific QA measure to compare planned and delivered isodose distributions in photon radiotherapy

BACKGROUND

The gamma index and dose-volume histogram (DVH)-based patient-specific quality assurance (QA) measures commonly applied in radiotherapy planning are unable to simultaneously deliver detailed locations and magnitudes of discrepancy between isodoses of planned and delivered dose distributions. By exploiting statistical classification performance measures such as sensitivity or specificity, compliance between a planned and delivered isodose may be evaluated locally, both for organs-at-risk (OAR) and the planning target volume (PTV), at any specified isodose level. Thus, a patient-specific QA tool may be developed to supplement those presently available in clinical radiotherapy.

MATERIALS AND METHODS

A method was developed to locally establish and report dose delivery errors in three-dimensional (3D) isodoses of planned (reference) and delivered (evaluated) dose distributions simultaneously as a function the dose level and of spatial location. At any given isodose level, the total volume of delivered dose containing the reference and the evaluated isodoses is locally decomposed into four subregions: true positive-subregions within both reference and evaluated isodoses, true negative-outside of both of these isodoses, false positive-inside the evaluated isodose but not the reference isodose, and false negatives-inside the reference isodose but not the evaluated isodose. Such subregions may be established over the whole volume of delivered dose. This decomposition allows the construction of a confusion matrix and calculation of various indices to quantify the discrepancies between the selected planned and delivered isodose distributions, over the complete range of values of dose delivered. The 3D projection and visualization of the spatial distribution of these discrepancies facilitates the application of the developed method in clinical practice.

RESULTS

Several clinical photon radiotherapy plans were analyzed using the developed method. In some plans at certain isodose levels, dose delivery errors were found at anatomically significant locations. These errors were not otherwise highlighted-neither by gamma analysis nor by DVH-based QA measures. A specially developed 3D projection tool to visualize the spatial distribution of such errors against anatomical features of the patient aids in the proposed analysis of therapy plans.

CONCLUSIONS

The proposed method is able to spatially locate delivery errors at selected isodose levels and may supplement the presently applied gamma analysis and DVH-based QA measures in patient-specific radiotherapy planning.

Intrinsic detector sensitivity analysis as a tool to characterize ArcCHECK and EPID sensitivity to variations in delivery for lung SBRT VMAT plans

PURPOSE

To investigate intrinsic sensitivity of an electronic portal imaging device (EPID) and the ArcCHECK detector and to use this in assessing their performance in detecting delivery variations for lung SBRT VMAT. The effect of detector spatial resolution and dose matrix interpolation on the gamma pass rate was also considered.

MATERIALS AND METHODS

Fifteen patients' lung SBRT VMAT plans were used. Delivery variations (errors) were introduced by modifying collimator angles, multi-leaf collimator (MLC) field sizes and MLC field shifts by ±5, ±2, and ±1 degrees or mm (investigating 103 plans in total). EPID and ArcCHECK measured signals with introduced variations were compared to measured signals without variations (baseline), using OmniPro-I'mRT software and gamma criteria of 3%/3 mm, 2%/2 mm, 2%/1 mm, and 1%/1 mm, to test each system's basic performance. The measurement sampling resolution for each was also changed to 1 mm and results compared to those with the default detector system resolution.

RESULTS

Intrinsic detector sensitivity analysis, that is, comparing measurement to baseline measurement, rather than measurement to plan, demonstrated the intrinsic constraints of each detector and indicated the limiting performance that users might expect. Changes in the gamma pass rates for ArcCHECK, for a given introduced error, were affected only by dose difference (DD %) criteria. However, the EPID showed only slight changes when changing DD%, but greater effects when changing distance-to-agreement criteria. This is pertinent for lung SBRT where the minimum dose to the target will drop dramatically with geometric errors. Detector resolution and dose matrix interpolation have an impact on the gamma results for these SBRT plans and can lead to false positives or negatives in error detection if not understood.

CONCLUSION

The intrinsic sensitivity approach may help in the selection of more meaningful gamma criteria and the choice of optimal QA device for site-specific dose verification.

Exploring the gamma surface: A new method for visualising modulated radiotherapy quality assurance results

PURPOSE

This work presents a novel method of visualising the results of patient-specific quality assurance (QA) for modulated radiotherapy treatment plans, using a three-dimensional distribution of gamma pass rates, referred to as the "gamma surface". The method was developed to aid in comparing borderline and failing QA plans, and to better compare patient-specific QA results between departments.

METHODS

Gamma surface plots were created for a representative sample of situations encountered during patient-specific QA. To produce a gamma surface plot, for each QA result, gamma pass rates were plotted as a heat map, with dose difference on one axis and distance-to-agreement on the other. This involved the calculation of 100 × 100 gamma pass rates over a dose difference and distance-to-agreement grid. As examples, five 220 × 680 arrays of dose points from radiotherapy treatment plans were compared against measurement data consisting of 21 × 66 arrays of dose points spaced 10 mm apart.

RESULTS

The gamma surface plots facilitated the rapid evaluation of criteria combinations for each plan, clearly highlighting the difference between plans that are modelled and delivered well, and those that are not. Large scale features were also evident in each surface, hinting at potential over-modulation, systematic dose errors, and small or large scale areas of disagreement in the distributions.

CONCLUSIONS

Gamma surface plots are a useful tool for investigating QA failures and borderline results, and have the capacity to grant insights into treatment plan QA performance that may otherwise be missed.

Design, Fabrication, and Validation of a Polymethyl Methacrylate Head Phantom for Dosimetric Verification of Cranial Radiotherapy Treatment Plans

Purpose:

The present study aims to design and fabricate a novel, versatile, and cost-effective Polymethyl Methacrylate (PMMA) head phantom for the dosimetric pretreatment verification of radiotherapy (RT) treatment plans.

Materials and Methods:

The head phantom designing involves slice-wise modeling of an adult head using PMMA. The phantom has provisions to hold detectors such as ionization chambers of different sizes, Gafchromic films, gel dosimeter, and optically stimulated luminescence dosimeter. For the point dose verification purpose, 15 volumetric modulated arc therapy patient plans were selected, and doses were measured using a CC13 ionization chamber. The percentage gamma passing rate was calculated for acceptance criteria 3%/3 mm and 2%/2 mm using OmniPro I’mRT film QA software, and Gafchromic EBT3 films were used for 2D planar dose verification.

Results:

Treatment planning system calculated, and the measured point doses showed a percentage deviation ranged from 0.26 to 1.92. The planar dose fluence measurements, for set acceptance criteria of 3%/3 mm and 2%/2 mm, percentages of points having gamma value <1 were in the range of 99.17 ± 0.25 to 99.88 ± 0.15 and 93.16 ± 0.38 to 98.89 ± 0.23, respectively. Measured dose verification indices were within the acceptable limit.

Conclusions:

The dosimetric study reveals that head phantom can be used for routine pretreatment verification for the cranial RT, especially for stereotactic radiosurgery/RT as a part of patient-specific quality assurance. The presently fabricated and validated phantom is novel, versatile, and cost-effective, and many institutes can afford it.

Three-dimensional dose reconstruction-based pretreatment dosimetric verification in volumetric modulated arc therapy for prostate cancer

Purpose

We performed three-dimensional (3D) dose reconstruction-based pretreatment verification to evaluate gamma analysis acceptance criteria in volumetric modulated arc therapy (VMAT) for prostate cancer.

Materials and Methods

Pretreatment verification for 28 VMAT plans for prostate cancer was performed using the COMPASS system with a dolphin detector. The 3D reconstructed dose distribution of the treatment planning system calculation (TC) was compared with that of COMPASS independent calculation (CC) and COMPASS reconstruction from the dolphin detector measurement (CR). Gamma results (gamma failure rate and average gamma value [GFR and γAvg]) and dose-volume histogram (DVH) deviations, 98%, 2% and mean dose-volume difference (DD_98%, DD_2% and DD_mean), were evaluated. Gamma analyses were performed with two acceptance criteria, 2%/2 mm and 3%/3 mm.

Results

The GFR in 2%/2 mm criteria were less than 8%, and those in 3%/3 mm criteria were less than 1% for all structures in comparisons between TC, CC, and CR. In the comparison between TC and CR, GFR and γAvg in 2%/2 mm criteria were significantly higher than those in 3%/3 mm criteria. The DVH deviations were within 2%, except for DD_mean (%) for rectum and bladder.

Conclusions

The 3%/3 mm criteria were not strict enough to identify any discrepancies between planned and measured doses, and DVH deviations were less than 2% in most parameters. Therefore, gamma criteria of 2%/2 mm and DVH related parameters could be a useful tool for pretreatment verification for VMAT in prostate cancer.

Clinical evaluation for the difference of absorbed doses calculated to medium and calculated to water by Monte Carlo method

BACKGROUND

To evaluate the difference of absorbed doses calculated to medium and to water by a Monte Carlo (MC) algorithm based treatment planning system (TPS), and to assess the potential clinical impact to dose prescription.

METHODS

Thirty patients, 10 nasopharyngeal cancer (NPC), 10 lung cancer and 10 bone metastases cases, were selected for this study. For each case, the treatment plan was generated using a commercial MC based TPS and dose was calculated to medium (D_m). The plan was recalculated for dose to water (D_w) using the same Monitor Units (MU) and control points. The differences between D_m and D_w were qualitatively evaluated by dose-volume parameters and by the plan subtraction method. All plans were measured using the MapCheck2, and gamma passing rates were calculated.

RESULTS

For NPC and Lung cases, the mean differences between D_w and D_m for the targets were less than 2% and the maximum difference was 3.9%. The maximum difference of D_2% for the organs at risk (OARs) was 6.7%. The maximum differences between D_w and D_m were as high as 10% in certain high density regions. For bone metastases cases, the mean differences between D_w and D_m for the targets were more than 2.2% and the maximum difference was 7.1%. The differences between D_w and D_m for the OARs were basically negligible. At 3%&3 mm criterion, the gamma passing rate of D_w plan and D_m plan were close (> 94%).

CONCLUSION

The differences between D_w and D_m has little clinical impact for most clinical cases. In bony structures the differences may become clinically significant if the target/OAR is receiving doses close to its tolerance limit which can potentially influence the selection or rejection of a particular plan.

Comparisons of volumetric modulated arc therapy (VMAT) quality assurance (QA) systems: sensitivity analysis to machine errors

BACKGROUND

In volumetric modulated arc therapy (VMAT), gantry angles, dose rate and the MLC positions vary with the radiation delivery. The quality assurance (QA) system should be able to catch the planning and machine errors. The aim of this study was to investigate the sensitivity of three VMAT QA systems to machine errors.

METHODS

Several types of potential linac machine errors unique to VMAT delivery were simulated in sinusoidal function of gantry angle, including gantry angle itself, MLC position and linac output. Two commercial QA systems, ArcCheck and Delta⁴, and an in-house developed EPID technique were compared in this study. Fifteen full arcs from head and neck plans were selected and modified to include five magnitudes of each type of error, resulting in measurements and γ analyses of 240 arcs on each system. Both qualitative and quantitative comparisons were performed using receiver operating characteristic (ROC), γ pass rate gradient, and overlap histogram methods.

RESULTS

In ROC analysis, the area under curve (AUC) represents the sensitivity and increases with the error magnitude. Using the criteria of 2 %/2 mm/2° (angle to agreement, ATA, only for EPID) and keeping AUC > 0.95, the minimum error detectable of ArcCheck, Delta⁴ and EPID are (2, 3, 3)° in gantry angle and (4, 2, 3) mm in MLC positions for the head and neck plans. No system is sensitive to the simulated output error, the AUC values were all below 0.70 even with 5 % output error. The γ gradient for gantry angle, MLC position and output errors are (-5.1, -2.6, -3.6)%/°, (-2.6, -7.1, -3.3)%/mm and (-0.2, -0.2, -0.3)%/% for ArcCheck, Delta⁴ and EPID, respectively. Therefore, these two analyses are consistent and support the same conclusion. The ATA parameter in EPID technique can be adjusted to tune its sensitivity.

CONCLUSIONS

We found that ArcCheck is more sensitive to gantry angle error and Delta⁴ is more sensitive to MLC position error. All three systems are not sensitive to the simulated output error. With additional analysis parameter, the EPID technique can be tuned to have optimal sensitivity and is able to perform QA for full field size with highest resolution. In addition, ROC analysis avoids the choice of γ pass rate threshold and is more robust compared with other analysis methods.

Film based verification of calculation algorithms used for brachytherapy planning-getting ready for upcoming challenges of MBDCA

Purpose

Well-known defect of TG-43 based algorithms used in brachytherapy is a lack of information about interaction cross-sections, which are determined not only by electron density but also by atomic number. TG-186 recommendations with using of MBDCA (model-based dose calculation algorithm), accurate tissues segmentation, and the structure's elemental composition continue to create difficulties in brachytherapy dosimetry. For the clinical use of new algorithms, it is necessary to introduce reliable and repeatable methods of treatment planning systems (TPS) verification. The aim of this study is the verification of calculation algorithm used in TPS for shielded vaginal applicators as well as developing verification procedures for current and further use, based on the film dosimetry method.

Material and methods

Calibration data was collected by separately irradiating 14 sheets of Gafchromic^® EBT films with the doses from 0.25 Gy to 8.0 Gy using HDR ¹⁹²Ir source. Standard vaginal cylinders of three diameters were used in the water phantom. Measurements were performed without any shields and with three shields combination. Gamma analyses were performed using the VeriSoft^® package.

Results

Calibration curve was determined as third-degree polynomial type. For all used diameters of unshielded cylinder and for all shields combinations, Gamma analysis were performed and showed that over 90% of analyzed points meets Gamma criteria (3%, 3 mm).

Conclusions

Gamma analysis showed good agreement between dose distributions calculated using TPS and measured by Gafchromic films, thus showing the viability of using film dosimetry in brachytherapy.

A retrospective analysis for patient-specific quality assurance of volumetric-modulated arc therapy plans

Volumetric-modulated arc therapy (VMAT) is now widely used clinically, as it is capable of delivering a highly conformal dose distribution in a short time interval. We retrospectively analyzed patient-specific quality assurance (QA) of VMAT and examined the relationships between the planning parameters and the QA results. A total of 118 clinical VMAT cases underwent pretreatment QA. All plans had 3-dimensional diode array measurements, and 69 also had ion chamber measurements. Dose distribution and isocenter point dose were evaluated by comparing the measurements and the treatment planning system (TPS) calculations. In addition, the relationship between QA results and several planning parameters, such as dose level, control points (CPs), monitor units (MUs), average field width, and average leaf travel, were also analyzed. For delivered dose distribution, a gamma analysis passing rate greater than 90% was obtained for all plans and greater than 95% for 100 of 118 plans with the 3%/3-mm criteria. The difference (mean ± standard deviation) between the point doses measured by the ion chamber and those calculated by TPS was 0.9% ± 2.0% for all plans. For all cancer sites, nasopharyngeal carcinoma and gastric cancer have the lowest and highest average passing rates, respectively. From multivariate linear regression analysis, the dose level (p = 0.001) and the average leaf travel (p < 0.001) showed negative correlations with the passing rate, and the average field width (p = 0.003) showed a positive correlation with the passing rate, all indicating a correlation between the passing rate and the plan complexity. No statistically significant correlation was found between MU or CP and the passing rate. Analysis of the results of dosimetric pretreatment measurements as a function of VMAT plan parameters can provide important information to guide the plan parameter setting and optimization in TPS.